Moleculin Biotech MBRX 深 沪
等待开盘 07-30 09:30:00 美东时间
0.7144
+0.164
+29.82%
华盛通- 最 高0.7168
- 今 开0.64
- 成交量 1680.54万股
- 最 低 0.575
- 昨 收 0.5503
- 总市值 1009.27万
- 52周最高 3.6499
- 市盈率 静 --
- 换手率 118.96%
- 52周最低 0.25
- 委 比 -82.20%
- 总股本 1412.75万
- 历史最高 862.20
- 量 比 7.69
- 振 幅 25.77%
- 历史最低 0.25
- 每 手 1
- 风险率 0.81%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Moleculin Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference
Moleculin Biotech's CEO, Walter Klemp, participated in a virtual investor conference, discussing his dedication to the company and its development programs. The on-demand video is available on the company's website. Moleculin is advancing Annamycin, a novel anthracycline for relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases, currently in Phase 3 trials. The company is also developing WP1066, an immu...
07-22 12:45
Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships
Moleculin Biotech, Inc. appoints Adriano Treve as a Strategic Advisor to enhance partnerships and advance its Phase 2B/3 MIRACLE trial for Annamycin in treating relapsed or refractory acute myeloid leukemia (AML). With over 40 years of experience at Roche, Treve brings expertise in global healthcare and market access. Moleculin expects his insights to strengthen strategic collaborations and accelerate development of key partnerships, aiming to cr...
07-17 12:25
Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition
Mainz Biomed has made significant strides in advancing its colorectal and pancreatic cancer screening technologies. The company initiated the eAArly DETECT 2 feasibility study for its next-gen CRC test, launched ColoAlert® in Switzerland, and entered collaborations to expand its product portfolio. Additionally, it secured a license for novel mRNA biomarkers for pancreatic cancer detection, with high sensitivity and specificity, and received publi...
07-15 12:01
Moleculin Biotech Enters New Stock Offering Agreement
The latest update is out from Moleculin Biotech ( ($MBRX) ). On July 11, 2025, ...
07-12 05:47
Moleculin Biotech Gains Approval for Phase 2B/3 AML Study
An announcement from Moleculin Biotech ( ($MBRX) ) is now available. On July 9,...
07-09 20:58
Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans
Moleculin Biotech, Inc. announced that the Regulation Agency for Medical and Pharmaceutical Activities (RAMPA) in Georgia has approved its Clinical Trial Application (CTA) for the pivotal Phase 2B/3 MIRACLE trial of Annamycin in combination with cytarabine for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML). The trial, which includes sites in the US, Europe, and the Middle East, has enrolled seven subj...
07-09 12:35
Moleculin Biotech Has Been Granted European Patent Number EP3990041 titled "METHOD OF RECONSTITUTING LIPOSOMAL ANNAMYCIN (FOR THE TREATMENT OF CANCER)
https://register.epo.org/application?number=EP20832031
07-08 04:02
Moleculin Biotech Faces Nasdaq Delisting Warning
Moleculin Biotech ( ($MBRX) ) has provided an announcement. On June 27, 2025, M...
06-28 05:32
